BridgeBio Pharma LLC, 10% Owner at Eidos Therapeutics, Inc. (EIDX), bought 40,653 shares at $13.96 ($542K) on 2018-12-10, disclosed to the SEC on 2018-12-13.
Open-market purchase of $542k EIDX by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.29 | 37,989 | $505K | 93.1% |
| 2 | $13.96 | 2,664 | $37K | 6.9% |
| Total | $13.33 avg | 40,653 | $542K | 100% |
| Filing → |
| EIDX | BUY | 2018-12-13 | $1.1M | — | Filing → |
| EIDX | SELL | 2018-12-12 | $542K | — | Filing → |
| EIDX | SELL | 2018-12-10 | $1.1M | — | Filing → |